Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Explore the detailed record of transactions filed by Sharp John P, Chief Financial Officer. Director active across 2 companies, notably PhaseBio Pharmaceuticals Inc. In total, 6 reports have been logged. History available since 20 May 2021. The latest transaction was filed on 20 May 2022 (Attribution). Regulator: SEC (Form 4). All data is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
6 of 6 declarations
John P. Sharp is the Chief Financial Officer at PhaseBio Pharmaceuticals Inc. He is responsible for the financial management of the company, including financial planning and analysis. His expertise is crucial in supporting the growth and sustainability of PhaseBio.